Recombinant human insulin-like growth factor I (rhIGF-I) and rhIGF-I/rhIGF-binding-protein-3: new growth treatment options?
Rosenbloom
Arlan L
AL
Division of Endocrinology, Department of Pediatrics, University of Florida College of Medicine, Gainesville, Florida, USA. rosenal@peds.ufl.edu <rosenal@peds.ufl.edu>
D000293:Adolescent; D002648:Child; D004359:Drug Therapy, Combination; D006130:Growth Disorders / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000627:therapeutic use*; D007334:Insulin-Like Growth Factor I / Q000172:deficiency / Q000627:therapeutic use*; D011994:Recombinant Proteins; D016896:Treatment Outcome
D018972:Insulin-Like Growth Factor Binding Protein 3; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I